Hot Investor Mandate: Korea Cross-Border Firm Actively Invests in Technologies that Address Oncology, Immunology, and Liver Disease Areas

2 May

A Korea-based investment firm manages several funds that focus primarily on the small- and mid-cap market in Korea, with around $500M AUM. Recently, the firm has closed a biotech-focused fund that will invest in global start-ups. The firm’s size of investment will depend on the stage of the company and will actively engage in follow-on investments as well. The firm actively seeks global opportunities.

The firm invests broadly across therapeutics, medical devices, and diagnostics, with the strongest interest in therapeutics. The firm is open to all types of modalities and is most interested in oncology and immunology indications as well as liver diseases such as NASH.

The firm seeks management teams with strong scientific expertise and experienced management teams. The firm may act as either a lead or co-investor and will not require a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: